Sonnet biotherapeutics announces publication detailing the discovery and development of son-1010, an albumin-binding il-12 fusion protein, demonstrating its mechanism of action

Pankaj mohan, ceo of sonnet discusses what this publication means in a virtual investor “what this means” segment; access here

SONN Ratings Summary

SONN Quant Ranking